Comparative Pharmacology
Head-to-head clinical analysis: MAXIBOLIN versus WINSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXIBOLIN versus WINSTROL.
MAXIBOLIN vs WINSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MAXIBOLIN (methandienone) is an anabolic steroid that binds to androgen receptors, increasing protein synthesis and nitrogen retention in muscle tissue. It also inhibits glucocorticoid receptors, reducing catabolism and promoting anabolic effects.
Winstrol (stanozolol) is an anabolic steroid derived from dihydrotestosterone. It binds to androgen receptors, increasing protein synthesis and inhibiting catabolic glucocorticoid activity, leading to enhanced muscle growth and reduced inflammation.
Oral: 2 mg three times daily; optimal response may require 4-8 mg daily for 2-3 weeks, then reduce to maintenance of 2-4 mg daily.
Adults: 2 mg orally three times daily, or 50 mg/mL intramuscularly once monthly (3-4 week intervals) for anabolic effect. Dose range: 1-3 mg/kg/day for hereditary angioedema.
None Documented
None Documented
Terminal elimination half-life of 9-10 hours; supports every-other-day dosing in androgen replacement therapy.
Terminal elimination half-life: 9-10 hours for oral administration (stanozolol); parenteral (IM) half-life extends to ~24 hours due to slow release from injection site. Clinical context: supports once-daily oral dosing or weekly IM dosing.
Primarily renal (90% as metabolites, 5% unchanged); biliary/fecal elimination accounts for approximately 10%.
Primarily renal: 90% as metabolites (glucuronide and sulfate conjugates) and 10% as unchanged drug; minor biliary/fecal elimination (<5%).
Category C
Category C
Anabolic Steroid
Anabolic Steroid